Delonix Bioworks Closes $14 Million Series Seed Financing to Accelerate the Development of its Innovative Synthetic Vaccines
News provided by
Share this article
Share this article
SHANGHAI, March 11, 2021 /PRNewswire/ Delonix Bioworks Ltd. (Delonix), a biotechnology company dedicated to developing the next generation vaccines with synthetic biology approaches, has recently closed a $14 million Series Seed financing led by Boehringer Ingelheim Venture Fund (BIVF) and IDG Capital, with participation from ZhenFund and an undisclosed investor. The financing will be used to accelerate the building of synthetic biology vaccine platforms and advance pipelines of synthetic vaccines to clinical trials.
Based in Shanghai, China, Delonix is working on innovative synthetic biology approaches to develop the next generation medical solutions to address global public health challenges. Delonix s synthetic biology and antigen discovery platforms enable rational design and programming of bact
Delonix Bioworks Closes $14 Million Series Seed Financing to Accelerate the Development of its Innovative Synthetic Vaccines
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators Company expands leadership team with CMO Philippe Wiesel, CBO Paul van der Horst and CFO Tolga Hassan AgomAb Therapeutics N.V. announced today the closing of a $74
million Series B financing round led by Redmile Group, with participation from Cormorant Asset Management. All previous investors also participated in the round, including Advent France Biotechnology, Andera Partners, Boehringer Ingelheim Venture Fund, Omnes Capital, Pontifax, and V-Bio Ventures. The proceeds of the Series B will be used to fund clinical proof of concept of the lead program AGMB-101, an HGF-mimetic agonistic antibody, which is currently progressing through IND-enabling studies. The capital will also support further growth of the company s pipeline of drug candidates designed to modulate regenerative pathways to induce functional organ recovery in acute and chronic diseases. In conjunction with the financi
Press release content from Business Wire. The AP news staff was not involved in its creation.
Eyevensys Named to French Tech 120 Program
February 15, 2021 GMT
PARIS & CAMBRIDGE, Mass. (BUSINESS WIRE) Feb 15, 2021
Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announced it has been accepted into the French Tech 120 program for 2021.
This government-backed program, run by La French Tech, offers support for 120 French startups considered late-stage and in a hypergrowth phase. Participating companies benefit from a variety of initiatives designed to support the needs of companies in this stage, such as unlimited access to government, public and ministry services, as well as tailored services from partner agencies. Participants will also benefit from collaboration with the French Tech 120 community, and a needs analysis that will help shape future regulations.
Rinri Therapeutics Appoints Experienced Life Science Executive Nick Higgins as Chairman
Extensive private and public company corporate development track record
Significant expertise in cell and gene therapy
News provided by
Share this article
Share this article
SHEFFIELD, England, Feb. 1, 2021 /PRNewswire/ Rinri Therapeutics, a biotechnology company developing a novel cell-based therapy to restore hearing, today announces the appointment of Nick Higgins as Chairman of the Board. He takes over from Dr Erica Whittaker who has served as Chair since the creation of Rinri Therapeutics.
Nick s career spans over 35 years in the life science industry during which he gained extensive knowledge of UK and US markets in both private and public sectors. Nick was the former Chief Executive Officer (CEO) of Intercytex Group plc, a company focused on the development and manufacturing of cell therapy products which was subsequently sold through a series of asset sales. He also served as Chi
vimarsana © 2020. All Rights Reserved.